JAZZ - Jazz Pharmaceuticals plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
129.08
-1.35 (-1.04%)
At close: 4:00PM EDT

129.08 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close130.43
Open130.92
Bid125.89 x 1300
Ask132.35 x 800
Day's Range126.57 - 130.92
52 Week Range113.52 - 184.00
Volume567,650
Avg. Volume542,803
Market Cap7.314B
Beta (3Y Monthly)0.96
PE Ratio (TTM)16.04
EPS (TTM)8.05
Earnings DateAug 5, 2019 - Aug 9, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est172.67
Trade prices are not sourced from all markets
  • PR Newswire14 hours ago

    Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi™ (solriamfetol)

    DUBLIN, June 17, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the U.S. Drug Enforcement Agency (DEA) has designated solriamfetol, also known as Sunosi, as a Schedule IV medicine. With U.S. Food and Drug Administration (FDA) approval on March 20, 2019, Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) approved to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).

  • Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?
    Zacks4 days ago

    Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Markit5 days ago

    See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.

    Jazz Pharmaceuticals PLC NASDAQ/NGS:JAZZView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for JAZZ with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $1.89 billion over the last one-month into ETFs that hold JAZZ are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Simply Wall St.12 days ago

    Should You Worry About Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Pay?

    In 2009 Bruce Cozadd was appointed CEO of Jazz Pharmaceuticals plc (NASDAQ:JAZZ). First, this article will compare CEO...

  • Why Is Jazz (JAZZ) Down 7.3% Since Last Earnings Report?
    Zacks12 days ago

    Why Is Jazz (JAZZ) Down 7.3% Since Last Earnings Report?

    Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • JAZZ or ZTS: Which Is the Better Value Stock Right Now?
    Zacks13 days ago

    JAZZ or ZTS: Which Is the Better Value Stock Right Now?

    JAZZ vs. ZTS: Which Stock Is the Better Value Option?

  • PR Newswire15 days ago

    Jazz Pharmaceuticals Appoints Dr. Robert Iannone as Executive Vice President, Research and Development

    DUBLIN, June 3, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced the appointment of Robert Iannone, M.D., M.S.C.E., as executive vice president, research and development, effective May 29, 2019. Dr. Iannone will lead Jazz's growing global R&D organization, including the pre-clinical development, clinical development, clinical operations, biostatistics, medical affairs, regulatory affairs, pharmacovigilance and safety functions. "Rob's extensive industry knowledge, leadership experience and strategic insights bring expertise in areas critical to our expanding capabilities as an innovative, global biopharmaceutical company with growing R&D investment and portfolio," said Daniel Swisher, president and chief operating officer at Jazz Pharmaceuticals.

  • Benzinga18 days ago

    The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 30) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Misonix, ...

  • Zacks.com featured highlights include: Gilead, Jazz, Amdocs, Arch Capital and Legg Mason
    Zacks21 days ago

    Zacks.com featured highlights include: Gilead, Jazz, Amdocs, Arch Capital and Legg Mason

    Zacks.com featured highlights include: Gilead, Jazz, Amdocs, Arch Capital and Legg Mason

  • Is Jazz (JAZZ) a Solid Growth Stock? 3 Reasons to Think " Yes "
    Zacks22 days ago

    Is Jazz (JAZZ) a Solid Growth Stock? 3 Reasons to Think " Yes "

    Jazz (JAZZ) is well positioned to outperform the market, as it exhibits above-average growth in financials.

  • 5 Best PEG Stocks Suitable for GARP Investors
    Zacks25 days ago

    5 Best PEG Stocks Suitable for GARP Investors

    While P/E alone only gives an idea of stocks that are trading at a discount, PEG, while adding the growth element to it, helps to identify stocks that have solid potential.

  • JAZZ vs. PCRX: Which Stock Should Value Investors Buy Now?
    Zacks29 days ago

    JAZZ vs. PCRX: Which Stock Should Value Investors Buy Now?

    JAZZ vs. PCRX: Which Stock Is the Better Value Option?

  • Is Jazz Pharmaceuticals (JAZZ) Stock Undervalued Right Now?
    Zackslast month

    Is Jazz Pharmaceuticals (JAZZ) Stock Undervalued Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • PR Newswirelast month

    Jazz Pharmaceuticals to Present New Data at Upcoming ASCO Annual Meeting and EHA Congress

    Data to be presented underscore commitment to developing life-changing medicines in hematology/oncology for people with limited or no treatment options DUBLIN , May 16, 2019 /PRNewswire/ -- Jazz Pharmaceuticals ...

  • Thomson Reuters StreetEventslast month

    Edited Transcript of JAZZ earnings conference call or presentation 7-May-19 8:30pm GMT

    Q1 2019 Jazz Pharmaceuticals PLC Earnings Call

  • 3 Small Drug Stocks Poised to Beat Q1 Earnings Estimates
    Zackslast month

    3 Small Drug Stocks Poised to Beat Q1 Earnings Estimates

    So far this earnings season, the going seems to be good for the medical sector. Let us take a glance at a few small drug companies, which are likely to beat on Q1 earnings.

  • 3 Reasons Why Growth Investors Shouldn't Overlook Jazz (JAZZ)
    Zackslast month

    3 Reasons Why Growth Investors Shouldn't Overlook Jazz (JAZZ)

    Jazz (JAZZ) is well positioned to outperform the market, as it exhibits above-average growth in financials.

  • PR Newswirelast month

    Jazz Pharmaceuticals Data to Showcase Ongoing Sleep Medicine Research at SLEEP 2019

    Fourteen abstracts highlight Jazz's breadth in sleep medicine research and commitment to developing treatment options for people living with debilitating sleep disorders DUBLIN , May 9, 2019 /PRNewswire/ ...

  • Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates
    Zackslast month

    Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates

    Jazz Pharmaceuticals (JAZZ) reports encouraging first-quarter 2019 earnings and revenues and maintains its guidance for 2019.

  • Jazz Pharmaceuticals Hits All the Right Notes in Q1
    Motley Foollast month

    Jazz Pharmaceuticals Hits All the Right Notes in Q1

    The drugmaker reported strong revenue and earnings growth thanks largely to solid growth for narcolepsy drug Xyrem.

  • Jazz Pharmaceuticals (JAZZ) Q1 2019 Earnings Call Transcript
    Motley Foollast month

    Jazz Pharmaceuticals (JAZZ) Q1 2019 Earnings Call Transcript

    JAZZ earnings call for the period ending March 31, 2019.